



ACCESS

Top-tier funds and direct investments are difficult to access and typically carry high investment minimums



EXPERIENCE

We have invested in 10 direct investment or co-investment platforms and over 15 funds since inception



ALIGNMENT

On average our employees have invested 30% of total capital in our direct and fund vehicles



RETURNS

Across all investment vehicles offered by BPAA, we have averaged greater than 3x MOIC for investors

RATIONALE FOR INVESTING IN BPAA PRIVATE EQUITY VEHICLES

BPAA provides access to unique private equity investment opportunities that are otherwise difficult to access for investors. These investments are designed to generate compelling long-term returns as a result of significant value-add created by BPAA and/or the underlying fund managers in which we invest. In each case, Bourne employees contribute significant capital alongside investors to ensure alignment of interests

11x
MOIC
on direct
investments

10 direct invest
& co invest
platforms
since inception

DIRECT INVEST CRITERIA

Equity Checks Up To \$1 billion
Healthcare Focus
Commercial Stage
Active Participation
Proven Management Team

CO-INVEST CRITERIA

Equity Checks Up To \$20 million
Industry Agnostic
Commercial Stage
Trusted Sponsor with Successful
Track Record

REPRESENTATIVE INVESTMENTS

DIRECT INVESTMENT PLATFORMS



UNDERLYING FUND INVESTMENTS



SPONSORS



DIRECT CO-INVESTMENTS





SECTOR EXPERTISE

Unlike generalist firms,
we concentrate solely
on healthcare
investment and
transaction advisory



GLOBAL NETWORK

We have
been involved in
transactions in 36
countries on
6 continents



360° APPROACH

As an investor; operator;
and advisor, we offer
perspectives from a
complete spectrum of
experiences



MAXIMIZED OUTCOMES

We understand the
necessity for the
alignment of interest
throughout the capital
structure

transaction range:
\$25 million
to **\$1 billion⁺**

TYPES OF ADVISORY WORK

Mergers & Acquisitions
Licensing / Partnering
Equity Capital
Debt Capital
Strategic Consulting

SECTOR FOCUS

Pharmaceuticals
Consumer Health / OTC
Pharma Services
Healthcare IT
Medical Device / Diagnostics

SELECT TOMBSTONES

2015
\$3,500,000,000

Bourne Partners served as
financial advisor to AMCo and
Cinven in the sale of AMCo
to Concordia Healthcare

BOURNE PARTNERS

2015
\$1,200,000,000

Bourne Partners served as the
exclusive financial advisor to Covis
Pharma in the sale of the majority
of its assets to Concordia Healthcare

BOURNE PARTNERS

2015
\$20,000,000

Bourne Partners served as the
exclusive financial advisor to Covis
Pharma in its acquisition of
one product from Shionogi

BOURNE PARTNERS

2015
\$8,500,000

Bourne Partners served as the
exclusive financial advisor to
YASOO Health in the sale of
AquADEKS to Actavis

BOURNE PARTNERS

\$4.7 bn
deals in 2015

SELECT CLIENTS & COUNTERPARTIES

